Login / register
To explore the effect of biparametric MRI-ultrasound(U/S) fusion prostate biopsy on detection rate of prostate cancer.
From August 2016 to July 2017, 107 patients with suspected prostatic lesions detected by more than 4 ng/ml of prostate specific antigen level (PSA). All subjects had received 3.0 T prebiopsy bi-parametric (diffusion-weighted and T2 weighted) magnetic resonance imaging (biparametric-MRI) and their MRI were evaluated with PIRAD ver 2.0. MRI-U/S fusion targeted prostate biopsy was performed in just lesions with more than three PIRAD score. All Patients were underwent random prostate biopsy basically. The results of targeted and random biopsy were compared to evaluate the detection rate of bi-parametric prostate MRI.
The mean age of the patients was 67 years and the mean PSA level was 8.1 ng/ml. The overall positive rate of fusion biopsy performed at more than PIRADS three was 55.8%, and the detection rate of clinically useful prostate cancer except for Gleason sum 6 point and low volume Gleason 3 + 4 was 52% for PIRADS 4 and 75% for PIRADs 5 in the same period. When comparing the concordance rates between systemic biopsy and biparametric MR-U/S fusion biopsy, it was confirmed that more clinically significant prostate cancer was found in fusion target biopsy. The most likely false positives would be PIRADS 3-point lesions.
In MR-U/S fusion biopsy, clinically useful prostate cancer was found better than systemic biopsy, and PIRADS 3-point lesion was more likely to be false-positive.